The Middle East diagnostic reagents for infectious diseases market size was estimated at USD 77.92 million in 2024, and is projected to reach USD 158.14 million by 2033, growing at a CAGR of 7.6% from 2025 to 2033. The market is being driven by an increase in regulatory authorizations for multiplex and high-sensitivity infectious disease reagent kits, as well as the expansion of national public-health and reference laboratories throughout the Middle East.
These factors are improving regional diagnostic capacity, allowing for faster detection of new and re-emerging pathogens. In 2024, WHO EMRO designated Saudi Arabia's Public Health Laboratory as a National Influenza Centre, increasing surveillance readiness and driving demand for validated, quality-assured diagnostic reagents. These developments, taken together, support the widespread use of advanced reagent platforms, particularly molecular and immunodiagnostic assays, in public health networks and clinical laboratories.
The Middle East diagnostic reagents market is being driven by increased regulatory approvals for multiplex and high-sensitivity kits, as well as the growth of national public-health and reference laboratories. Regulatory endorsements, such as Thermo Fisher Scientific's FDA-approved respiratory pathogen panels, which was implemented in UAE laboratories in 2024, boost confidence in advanced reagent use. The expansion of national laboratories in 2023, including Egypt's Central Public Health Laboratory, which is expected to ramp up molecular testing and, improves pathogen surveillance capabilities. These developments allow for faster sample processing, broader geographic coverage, and increased procurement of validated reagents. Government-led investments in laboratory infrastructure enable smaller hospitals and clinics to perform sophisticated diagnostic testing. By combining regulatory support with expanded laboratory reach, the region ensures that multiplex, high-sensitivity reagents are available in both the public and private sectors, strengthening preparedness against endemic and emerging infectious diseases.
The market is being driven by the adoption of multiplex testing and automated platforms, which improve diagnostic throughput and shorten turnaround times. Multiplex reagents enable the simultaneous detection of multiple pathogens from a single sample, saving reagents and increasing operational efficiency. For instance, IDT's integrated PCR reagent panels, which were introduced in Bahraini laboratories in 2025, enable rapid detection of respiratory and enteric pathogens, allowing for same-day results. Automated platforms, such as SeraCare's AccuPlex systems, improve nucleic acid extraction, amplification, and reporting while reducing manual labor and human error. These technologies allow laboratories to process larger sample volumes, which is critical during sudden outbreaks or seasonal epidemics. As a result, reagent utilization rises alongside faster, more reliable diagnostics, meeting the growing clinical and public-health demand for high-throughput solutions. Automation and multiplexing are accelerating market adoption by enabling cost-effective, accurate, and rapid infectious disease testing throughout the region.
The growing need for AMR surveillance is a significant driver of reagent demand. Multiplex bacterial-resistance gene detection kits are essential for identifying pathogens with resistance genes such as NDM, KPC, and OXA variants, thereby promoting rational antibiotic use. Bio-Rad Laboratories' multiplex AMR panels were installed in Qatar's Hamad Medical Corporation in 2024, allowing hospitals to track resistance trends in real time. Regional health authorities use these reagents for population surveillance, outbreak management, and stewardship programs. Continuous monitoring informs treatment guidelines and slows the spread of resistant strains, increasing the need for high-quality reagents. As hospitals and public health labs incorporate these kits into routine workflows, their use increases steadily. AMR-focused diagnostics ensure that laboratories can efficiently provide actionable insights, while also assisting national health systems in combating the growing threat of drug-resistant infections in both clinical and community settings.
In addition, persistent infectious disease burdens and outbreak risks continue to fuel the Middle Eastern reagents market. High-sensitivity kits are critical for the rapid detection of emerging and endemic pathogens, especially in areas with frequent mass gatherings. For instance, Kuwait expanded Dengue virus testing in 2025 in response to local outbreaks, highlighting the importance of rapid, multiplex reagents in outbreak containment. Similarly, the region's vulnerability to MERS-CoV and seasonal influenza drives up demand for sensitive respiratory pathogen panels. Manufacturers are responding with specialized reagents that can detect multiple viral and bacterial agents at the same time, allowing for earlier diagnosis, more timely intervention, and better patient management. The combination of high disease prevalence, mobile populations, and public-health preparedness initiatives ensures consistent demand for validated diagnostic reagents, which fuels the market's expansion.
This product will be delivered within 1-3 business days.
These factors are improving regional diagnostic capacity, allowing for faster detection of new and re-emerging pathogens. In 2024, WHO EMRO designated Saudi Arabia's Public Health Laboratory as a National Influenza Centre, increasing surveillance readiness and driving demand for validated, quality-assured diagnostic reagents. These developments, taken together, support the widespread use of advanced reagent platforms, particularly molecular and immunodiagnostic assays, in public health networks and clinical laboratories.
The Middle East diagnostic reagents market is being driven by increased regulatory approvals for multiplex and high-sensitivity kits, as well as the growth of national public-health and reference laboratories. Regulatory endorsements, such as Thermo Fisher Scientific's FDA-approved respiratory pathogen panels, which was implemented in UAE laboratories in 2024, boost confidence in advanced reagent use. The expansion of national laboratories in 2023, including Egypt's Central Public Health Laboratory, which is expected to ramp up molecular testing and, improves pathogen surveillance capabilities. These developments allow for faster sample processing, broader geographic coverage, and increased procurement of validated reagents. Government-led investments in laboratory infrastructure enable smaller hospitals and clinics to perform sophisticated diagnostic testing. By combining regulatory support with expanded laboratory reach, the region ensures that multiplex, high-sensitivity reagents are available in both the public and private sectors, strengthening preparedness against endemic and emerging infectious diseases.
The market is being driven by the adoption of multiplex testing and automated platforms, which improve diagnostic throughput and shorten turnaround times. Multiplex reagents enable the simultaneous detection of multiple pathogens from a single sample, saving reagents and increasing operational efficiency. For instance, IDT's integrated PCR reagent panels, which were introduced in Bahraini laboratories in 2025, enable rapid detection of respiratory and enteric pathogens, allowing for same-day results. Automated platforms, such as SeraCare's AccuPlex systems, improve nucleic acid extraction, amplification, and reporting while reducing manual labor and human error. These technologies allow laboratories to process larger sample volumes, which is critical during sudden outbreaks or seasonal epidemics. As a result, reagent utilization rises alongside faster, more reliable diagnostics, meeting the growing clinical and public-health demand for high-throughput solutions. Automation and multiplexing are accelerating market adoption by enabling cost-effective, accurate, and rapid infectious disease testing throughout the region.
The growing need for AMR surveillance is a significant driver of reagent demand. Multiplex bacterial-resistance gene detection kits are essential for identifying pathogens with resistance genes such as NDM, KPC, and OXA variants, thereby promoting rational antibiotic use. Bio-Rad Laboratories' multiplex AMR panels were installed in Qatar's Hamad Medical Corporation in 2024, allowing hospitals to track resistance trends in real time. Regional health authorities use these reagents for population surveillance, outbreak management, and stewardship programs. Continuous monitoring informs treatment guidelines and slows the spread of resistant strains, increasing the need for high-quality reagents. As hospitals and public health labs incorporate these kits into routine workflows, their use increases steadily. AMR-focused diagnostics ensure that laboratories can efficiently provide actionable insights, while also assisting national health systems in combating the growing threat of drug-resistant infections in both clinical and community settings.
In addition, persistent infectious disease burdens and outbreak risks continue to fuel the Middle Eastern reagents market. High-sensitivity kits are critical for the rapid detection of emerging and endemic pathogens, especially in areas with frequent mass gatherings. For instance, Kuwait expanded Dengue virus testing in 2025 in response to local outbreaks, highlighting the importance of rapid, multiplex reagents in outbreak containment. Similarly, the region's vulnerability to MERS-CoV and seasonal influenza drives up demand for sensitive respiratory pathogen panels. Manufacturers are responding with specialized reagents that can detect multiple viral and bacterial agents at the same time, allowing for earlier diagnosis, more timely intervention, and better patient management. The combination of high disease prevalence, mobile populations, and public-health preparedness initiatives ensures consistent demand for validated diagnostic reagents, which fuels the market's expansion.
Middle East Diagnostic Reagents for Infectious Diseases Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. The report has segmented the Middle East diagnostic reagents for infectious infectious diseases market based on product, disease area, technology, end use, and country:Product Outlook (Revenue, USD Million, 2021-2033)
- Molecular Reagents
- Immunoassay Reagents
- Rapid Test Reagents
- Serology Reagents
- Controls And Calibrators
- Other Reagents
Disease Area Outlook (Revenue, USD Million, 2021-2033)
- Respiratory Infections
- Vector-Borne & Tropical Diseases
- Enteric Infections
- Sexually Transmitted Infections (STIs)
- Other Emerging / High-Burden Infectious Diseases
Technology Outlook (Revenue, USD Million, 2021-2033)
- Molecular Diagnostics
- Immunoassays
- Point-of-Care Reagents
- Multiplex Platforms
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals & Clinics
- Diagnostic Laboratories
- Point-of-Care / Decentralized Testing Sites
- Public Health Agencies & National Reference Labs
- Academic & Research Institutes
Regional Outlook (Revenue, USD Million, 2021-2033)
- Middle East
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Middle East Diagnostic Reagents for Infectious Diseases Market Variables, Trends & Scope
Chapter 4. Middle East Diagnostic Reagents for Infectious Diseases Market: Product Estimates & Trend Analysis
Chapter 5. Middle East Diagnostic Reagents for Infectious Diseases Market: Disease Area Estimates & Trend Analysis
Chapter 6. Middle East Diagnostic Reagents for Infectious Diseases Market: Technology Estimates & Trend Analysis
Chapter 7. Middle East Diagnostic Reagents for Infectious Diseases Market: End Use Estimates & Trend Analysis
Chapter 8. Middle East Diagnostic Reagents for Infectious Diseases Market: Country Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Middle East Diagnostic Reagents for Infectious Diseases market report include:- F. Hoffmann-La Roche Ltd
- Abbott
- QIAGEN
- bioMérieux
- Bio-Rad Laboratories, Inc.
- Seegene Inc.
- Thermo Fisher Scientific, Inc.
- SD Biosensor
- Mindray
- Astragene
- Hologic
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | December 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 77.92 Million |
| Forecasted Market Value ( USD | $ 158.14 Million |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Middle East |
| No. of Companies Mentioned | 11 |
